REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results for Q2 2026 on Thursday, July 30th. The company reported earnings of $14.29 per share, beating estimates of $10.53 by $3.76. The company also reported revenue of $4,290,700,000, beating estimates of $3,891,689,691 by $399,010,309.
You can see Quiver Quantitative's $REGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
REGENERON PHARMACEUTICALS Insider Trading Activity
REGENERON PHARMACEUTICALS insiders have traded $REGN stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.
Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:
- JASON PITOFSKY (SVP Controller) has made 0 purchases and 11 sales selling 2,036 shares for an estimated $1,585,058.
- HUDA Y ZOGHBI has made 0 purchases and 11 sales selling 1,638 shares for an estimated $1,279,811.
- ARTHUR F RYAN has made 0 purchases and 26 sales selling 400 shares for an estimated $278,406.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
REGENERON PHARMACEUTICALS Hedge Fund Activity
We have seen 563 institutional investors add shares of REGENERON PHARMACEUTICALS stock to their portfolio, and 630 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 1,172,994 shares (+176.5%) to their portfolio in Q1 2026, for an estimated $898,970,871
- FMR LLC removed 801,374 shares (-34.5%) from their portfolio in Q1 2026, for an estimated $614,165,019
- TWO SIGMA INVESTMENTS, LP added 531,085 shares (+188.9%) to their portfolio in Q1 2026, for an estimated $407,018,233
- MARSHALL WACE, LLP removed 478,198 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $366,486,165
- HOLOCENE ADVISORS, LP removed 460,723 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $353,093,499
- MILLENNIUM MANAGEMENT LLC removed 317,038 shares (-83.5%) from their portfolio in Q1 2026, for an estimated $242,974,752
- ACADIAN ASSET MANAGEMENT LLC removed 294,604 shares (-66.1%) from their portfolio in Q1 2026, for an estimated $225,781,559
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
REGENERON PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $REGN stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 05/15.
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
- REPRESENTATIVE JULIA LETLOW purchased up to $15,000 on 02/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
REGENERON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HSBC issued a "Buy" rating on 07/06/2026
- Barclays issued a "Overweight" rating on 04/30/2026
- Truist Securities issued a "Buy" rating on 04/30/2026
- Cantor Fitzgerald issued a "Overweight" rating on 02/02/2026
To track analyst ratings and price targets for REGENERON PHARMACEUTICALS, check out Quiver Quantitative's $REGN forecast page.
REGENERON PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 18 analysts offer price targets for $REGN in the last 6 months, with a median target of $809.5.
Here are some recent targets:
- Biren Amin from Piper Sandler set a target price of $854.0 on 07/09/2026
- Matthew Harrison from Morgan Stanley set a target price of $730.0 on 07/08/2026
- Gregory Renza from Truist Securities set a target price of $769.0 on 07/07/2026
- Brian Abrahams from RBC Capital set a target price of $696.0 on 07/07/2026
- Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
- Carter Gould from Cantor Fitzgerald set a target price of $750.0 on 07/06/2026
- Rajesh Kumar from HSBC set a target price of $880.0 on 07/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
